

Challenges for foundations and cancer research organisations

Jacques RAYNAUD
Honorary President
Scientific Adviser to the President

- **I have no actual or potential conflict of interest in relation to this presentation.**

1st French non-profit organization entirely dedicated to cancer research
Our mission: prevent and cure cancer through research

Support all fields of oncology: From biology to basic science and clinical research,
epidemiology and social sciences


Partner with the key French stakeholders of cancer research:
Inserm, CNRS, INCa, UNICANCER...

100% supported by private donors
Independent from public agencies and private companies



Our approach: gathering expertise and excellence to foster therapeutic innovations and accelerate their transfer to the clinical stage

Our goal: cure 2 cancer patients out of 3 within 10 years



Stakeholders information and mobilisation



New therapeutic strategies validation



Therapeutic innovation support



Knowledge generation

Gathering ideas, expertise and excellence

➤ **Scientific Strategy Committee**

president: Pr Thomas Tursz

Pr Hans-Olov ADAMI • Pr René BERNARDS • Pr Fred BOSMAN • Pr Carlos CALDAS •
Dr Stephen FRIEND • Pr Vincent GRÉGOIRE • Pr Thomas KRUMMEL •
Pr John MENDELSON • Pr Martine PICCART • Pr Ulrik RINGBORG • Pr Éric SOLARY •
Pr Robert WEINBERG • Pr Otmar WIESTLER • Pr Jessica ZUCMAN-ROSSI

The SCC shapes and evaluates the scientific strategy of the ARC Foundation.

➤ **Scientific Committee**

president: Pr Eric Solary (Gustave Roussy)

more than 100 experts select research grants

➤ **Board of Administrators**

president: Michel Pébereau

votes scientific decisions

All members are volunteers.

2014 operating budget (social mission & operating costs): 38 M€ (42,6 M\$)


311 new projects funded in 2014, split in 3 main actions


Continuous support to
basic research teams


Education of young
and future talents

Innovation transfer to
the patients


Prevention
Precision/personalised medicine
Technological innovations










Open trials



Objective: Activation delay

	AcSé Crizotinib	AcSé Vemurafenib
CPP authorization	2013/05/13	2014/06/10
ANSM authorization	2013/05/30	2014/08/01
1 st settlement	2013/07/23	2014/10/01
1 st patient	2013/08/05	2014 /10/13



1/ Cohort Lung ROS1


Authors : D. Moro-Sibilot, L. Faivre, G. Zalcman, M. Pérol, F. Barlesi, J. Otto, I. Monnet, A-B. Cortot, M. Wislez, H. Léna, J. Mazières, X. Durando, S. Lantuejoul, I. Rouquette, A. McLeer Florin, G. Ferretti, N. Hoog-Labouret, F. Nowak, M. Jimenez, G. Vassal.


« Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial »

2/ All tumors with MET amplification

Authors : G. Vassal, MC. Le Deley, C. Tournigand, T. Aparicio, I. Ray-Coquard, L. Taillandier, B. Escudier, B. You, A. Gonçalves, C. Lombard-Bohas, JF. Seitz, T. André, JP. Merlio, L. Amould, G. Ferretti, Y. Menu, T. Mortier, E. Lonchamp, C. Mahier-Aït Oukhatar, D. Moro-Sibilot.

« Activity of Crizotinib in relapsed MET amplified malignancies: Results of the French AcSé Program »





patient mobilization

regulatory agencies

SOCIETAL CHALLENGES

data confidentiality

*many stakeholders with
conflicting interests*


*structural &
organizational challenges*

philanthropy

FINANCIAL CHALLENGES

cost of research (bench and clinical)

*access to drugs &
their exponential cost*



The ARC Foundation faces these challenges by:

- **MAKING CHOICES:** we invest significantly in early stage trials
- **TAKING RISKS** that other organisations won't easily take
- **CONNECTING ALL STAKEHOLDERS**, at a national and international level. We never lose sight of what is at stake:
 - 150 000 deaths every year in France, 8,2 millions worldwide
 - as cancer becomes a chronic disease, quality of life is an important goal

The ARC Foundation joined the WIN consortium in 2014.

→ Member of the General Assembly, the Directorate and the SAB.

Why WIN is unique?

- A worldwide strategy
- A crucial asset for precision medicine and biomarker discovery
- A consortium building bridges between all stakeholders:
 - Technology companies
 - Pharmaceuticals
 - Academics
 - Healthpayors
 - Funding organizations

Why the ARC Foundation is committed to funding WINTHER trial?

WINTHER, the founding trial of WIN, represents an investment of 2 M€

- 1st time transcriptome is used to inform therapy
- 1st time normal tissue is used as control
- 1st time objective to give access to a large number of patients to a personalized therapy

The lessons we take from our experience with the WINTHER trial

- learning at the laboratory level and SIMS
- no morbidity related to dual biopsy
- weekly communication to discuss each patient
- EU qualifies as a success story!

« Insanity: doing the same thing over and over again and expecting different results » (Einstein)

Challenges for foundations and cancer research organisations

Jacques RAYNAUD
Honorary President
Scientific Adviser to the President